Crossmark

<scp>IFN</scp> λ is a potent anti‐influenza therapeutic without the inflammatory side effects of <scp>IFN</scp> α treatment

Crossref DOI link: https://doi.org/10.15252/emmm.201606413

Published Online: 2016-08-12

Published Print: 2016-09

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Davidson, Sophia

McCabe, Teresa M https://orcid.org/0000-0002-0298-1426
Crotta, Stefania https://orcid.org/0000-0003-4676-8616
Gad, Hans Henrik

Hessel, Edith M

Beinke, Soren https://orcid.org/0000-0002-2850-5241
Hartmann, Rune https://orcid.org/0000-0003-1159-066X
Wack, Andreas https://orcid.org/0000-0001-5226-2991
Funding

Funding for this research was provided by:

Francis Crick Institute

Cancer Research UK

Wellcome Trust

Medical Research Council (U117597139)

Biotechnology and Biological Sciences Research Council (BB/K501475/1)

Sundhed og Sygdom, Det Frie Forskningsråd (11‐107588)
License Information

Version of Record valid from 2016-08-12
More Information

Publication History

Received: 2016-03-16

Accepted: 2016-07-21

Published: 2016-08-12